跳至主要内容
临床试验/NCT00473265
NCT00473265已完成2 期

Bone Properties in Hypoparathyroidism: Effects of PTH

John P. Bilezikian1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2004年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
68
试验地点
1
主要终点
Requirements for Calcium Supplementation

研究概览

简要总结

Whereas much information is known about the properties of bone in primary hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The purpose of this research project is to test the hypothesis that the skeleton in hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and microarchitectural features. We will also test the hypothesis that the skeleton is dependent upon PTH for normal structure and function. Using non-invasive approaches as well as direct analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized. With each patient serving as his/her own control, we will determine how, to what extent, and in what ways the administration of PTH restores skeletal dynamics and structure to the hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH action on bone gained by our many years of studying PTH overexpression in primary hyperparathyroidism. This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis.

详细描述

A detailed description of the methods used in this study include the following: direct analysis of bone itself. skeletal dynamics and structure such as dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hypoparathyroidism

排除标准

  • Bisphosphonate use

研究组 & 干预措施

PTH(1-84)

Experimental

100mcg of PTH1-84 every other day, every day, or every three days

干预措施: PTH (Drug)

结局指标

主要结局

Requirements for Calcium Supplementation

时间窗: 2 years

Serum and urinary calcium levels maintained by change in requirements for calcium supplementation

次要结局

  • Percent Change in BMD From Baseline to 24 Months by DXA(baseline versus 24 months)
  • Trabecular Width(baseline versus two years)
  • Trabecular Number(baseline versus two years)
  • Cortical Porosity(baseline versus two years)
  • Mineralizing Surface(baseline versus one year)

研究者

发起方
John P. Bilezikian
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

John P. Bilezikian

Dorothy L. and Daniel H. Silberberg Professor of Medicine and Pharmacology

Columbia University

研究点 (1)

Loading locations...

相似试验